The Enterprise Value as of December 2024 (TTM) for Codexis, Inc. (CDXS) is 411.28M

According to Codexis, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 411.28M. This represents a change of 91.91% compared to the average of 214.31M of the last 4 quarters.

Codexis, Inc. (CDXS) Historical Enterprise Value (quarterly & annually)

How has CDXS Enterprise Value performed in the past?

The mean historical Enterprise Value of Codexis, Inc. over the last ten years is 590.97M. The current 411.28M Enterprise Value has changed 6.86% with respect to the historical average. Over the past ten years (40 quarters), CDXS's Enterprise Value was at its highest in in the December 2021 quarter at 1.93B. The Enterprise Value was at its lowest in in the December 2014 quarter at 70.89M.

Codexis, Inc. (CDXS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Codexis, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Codexis, Inc. (CDXS) Average Enterprise Value

How has CDXS Enterprise Value performed in the past?

The current Enterprise Value of Codexis, Inc. (CDXS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Codexis, Inc. (CDXS) Enterprise Value vs. Peers

How is CDXS’s Enterprise Value compared to its peers?

Codexis, Inc.’s Enterprise Value is less than Nuvation Bio Inc. (930.27M), greater than Lyell Immunopharma, Inc. (130.21M), greater than Century Therapeutics, Inc. (89.16M), greater than Generation Bio Co. (143.59M), greater than Shattuck Labs, Inc. (12.78M), greater than Foghorn Therapeutics Inc. (260.47M), greater than Monte Rosa Therapeutics, Inc. (351.25M), less than Kymera Therapeutics, Inc. (2.62B), less than Nurix Therapeutics, Inc. (1.31B), greater than Kezar Life Sciences, Inc. (29.92M), less than Mineralys Therapeutics, Inc. (539.76M), greater than Nkarta, Inc. (194.33M), greater than NGM Biopharmaceuticals, Inc. (69.72M), less than Cullinan Oncology, Inc. (614.81M), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Revolution Medicines, Inc. (7.98B),

Build a custom stock screener for Codexis, Inc. (CDXS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Codexis, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Codexis, Inc. (CDXS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Codexis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.